Overview

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Status:
Active, not recruiting

Trial end date:
2021-10-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

Phase:

Phase 2

Details

Lead Sponsor:

Clovis Oncology, Inc.

Collaborators:

Foundation Medicine
Myriad Genetics, Inc.

Treatments:

Rucaparib